Response according to histology in patients receiving therapeutic-dose levels and above of umbralisib (1200 mg initial or >600 mg micronized)
| Histology . | Response, n/N (%) . | ||||
|---|---|---|---|---|---|
| ORR . | CR . | PR . | Stable disease . | PD . | |
| All patients | 29/57 (51) | 12/57 (21) | 17/57 (30) | 11/57 (19) | 17/57 (30) |
| CLL/SLL | 10/15 (67) | 2/15 (13) | 8/15 (53) | 2/15 (13) | 3/15 (20) |
| Aggressive B-NHL | 6/22 (27) | 3/22 (14) | 3/22 (14) | 5/22 (23) | 11/22 (50) |
| DLBCL | 5/19 (26) | 3/19 (16) | 2/19 (11) | 5/19 (26) | 9/19 (47) |
| MCL | 0/2 (0) | — | — | — | 2/2 (100) |
| RT | 1/1 (100) | — | 1/1 (100) | — | — |
| Indolent B-NHL | 13/20 (65) | 7/20 (35) | 6/20 (30) | 4/20 (20) | 3/20 (15) |
| FL | 8/15 (53) | 4/15 (27) | 4/15 (27) | 4/15 (27) | 3/15 (20) |
| MZL | 5/5 (100) | 3/5 (60) | 2/5 (40) | — | — |
| Histology . | Response, n/N (%) . | ||||
|---|---|---|---|---|---|
| ORR . | CR . | PR . | Stable disease . | PD . | |
| All patients | 29/57 (51) | 12/57 (21) | 17/57 (30) | 11/57 (19) | 17/57 (30) |
| CLL/SLL | 10/15 (67) | 2/15 (13) | 8/15 (53) | 2/15 (13) | 3/15 (20) |
| Aggressive B-NHL | 6/22 (27) | 3/22 (14) | 3/22 (14) | 5/22 (23) | 11/22 (50) |
| DLBCL | 5/19 (26) | 3/19 (16) | 2/19 (11) | 5/19 (26) | 9/19 (47) |
| MCL | 0/2 (0) | — | — | — | 2/2 (100) |
| RT | 1/1 (100) | — | 1/1 (100) | — | — |
| Indolent B-NHL | 13/20 (65) | 7/20 (35) | 6/20 (30) | 4/20 (20) | 3/20 (15) |
| FL | 8/15 (53) | 4/15 (27) | 4/15 (27) | 4/15 (27) | 3/15 (20) |
| MZL | 5/5 (100) | 3/5 (60) | 2/5 (40) | — | — |